ReviewCurrent topics in medicinal chemistry2026
Role of New Biomarkers in the Early Diagnosis of Gestational Diabetes: A Mini Review.
Review in Current topics in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gestational diabetes (GDM) has become a major public health problem in recent years and one of the most debated topics in women's health. GDM is associated with serious health consequences for both the mother and the child in the short and long term. The prevalence of GDM varies between 0.6% and 20% (depending on the detection method, gestational age, and the population studied). Genetic, nutritional, epigenetic, immunological, and hormonal components have been identified in its pathophysiology. Today, the importance of identifying a biomarker to detect GDM from the beginning of pregnancy in women at high risk of developing GDM is frequently emphasized. In recent years, adipokines and cytokines have been reported to play important roles in the metabolic changes underlying GDM. The purpose of this study was to reveal the potential and importance of the recently identified chemerin, omentin-1, resistin, visfatin, and asprosin peptides with different mechanisms of action in the pathogenesis of GDM.
Indexed as
Identifiers
40605171What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.